ArticlePloS one2026
Fcer1g and St3gal1: Macrophage-associated angiogenesis biomarkers and therapeutic targets in sepsis-induced acute lung injury.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lung injury (ALI) involves the release of growth factors and inflammatory mediators from damaged pulmonary tissues, fostering endothelial cell proliferation, migration, and vascular lumen formation, thereby driving pathological angiogenesis. Macrophages contribute to angiogenesis and vascular homeostasis, but their dysregulation in pathological states worsens vascular dysfunction. This study aims to identify macrophage-associated angiogenesis-related genes as novel diagnostic biomarkers and therapeutic targets for sepsis-associated ALI (SALI).
methodsTranscriptomic datasets from the GEO database were analyzed using differential expression profiling and weighted gene co-expression network analysis (WGCNA) to identify candidate genes. These candidates were compared with macrophage- and angiogenesis-related gene sets from GENECARDS for functional prioritization. Three machine learning algorithms (LASSO regression, random forest, and SVM) were employed to refine predictive biomarkers, followed by immune infiltration analysis (via CIBERSORT) to assess correlations with immune subsets. Single-cell RNA sequencing and RT-PCR were used for spatial validation of gene expression.
resultsTwo macrophage-associated angiogenesis-related genes, Fcer1g (FCER1G) and St3gal1 (ST3GAL1), were identified as key biomarkers. Both genes showed significant upregulation in the training cohort (p < 0.001) and independent validation sets (p < 0.05), with robust diagnostic accuracy (AUC > 0.85). Immune correlation analysis indicated strong positive associations with macrophage infiltration (p < 0.01), particularly M2-polarized subsets. scRNA-seq confirmed their predominant expression in macrophage clusters, with increased activity in SALI tissues (log2FC > 2.0, p < 0.001).
conclusionsIn mouse in vivo studies, Fcer1g and St3gal1 were shown to precisely mediate intricate macrophage-endothelial cell interactions via glycoimmune signaling pathways at the molecular level. This interaction finely modulates endothelial cell activation and drives angiogenic remodeling, critically impacting SALI progression. Given the physiological and pathological parallels between mice and humans, our findings offer a theoretical underpinning for subsequent human - oriented research. Moving forward, efforts should focus on verifying the expression patterns, action mechanisms, and diagnostic/therapeutic potential of these genes in relation to human SALI - associated signatures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.